Statins for Primary Prevention of Cardiovascular Disease-With PREVENT, What's a Clinician to Do?

JAMA. 2024 Sep 24;332(12):961-962. doi: 10.1001/jama.2024.13887.
No abstract available

Plain language summary

This Viewpoint explores decision thresholds and the evidence that informs them as well as how clinicians may respond to an updated risk estimation model, such as the Predicting Risk of cardiovascular disease EVENTs equations.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Age Factors
  • Aged
  • American Heart Association
  • Cardiovascular Diseases* / blood
  • Cardiovascular Diseases* / epidemiology
  • Cardiovascular Diseases* / etiology
  • Cardiovascular Diseases* / prevention & control
  • Cholesterol, LDL / blood
  • Clinical Decision-Making
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors* / therapeutic use
  • Hyperlipoproteinemias* / blood
  • Hyperlipoproteinemias* / complications
  • Hyperlipoproteinemias* / diagnosis
  • Hyperlipoproteinemias* / drug therapy
  • Middle Aged
  • Practice Guidelines as Topic
  • Primary Prevention* / methods
  • Primary Prevention* / standards
  • Risk Assessment / methods
  • Risk Assessment / standards

Substances

  • Cholesterol, LDL
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors